专业监测看板

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

药物 / 成分：Ixabepilone Injection

登记的停止原因（原文）：Company Decision

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

药物 / 成分：Spesolimab - solution for infusion、Placebo matching to spesolimab - solution for infusion、Spesolimab - solution for injection、Placebo matching to spesolimab - solution for injection

Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

药物 / 成分：CD38-SADA:177Lu-DOTA Complex

登记的停止原因（原文）：Study is terminated by Sponsor decision due to recruitment challenges.

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

药物 / 成分：TCD601、Tacrolimus (TAC)、Corticosteroids (CS)、Mycophenolate Mofetil (MMF)

登记的停止原因（原文）：After enrolment was complete, and sufficient data was collected to fully characterize the highest dose cohort, study follow up was terminated by the sponsor for non-safety related reasons.

The Role of Secondary Bile Acids in Intestinal Inflammation

药物 / 成分：ursodiol (ursodeoxycholic acid, UDCA)

登记的停止原因（原文）：Lack of recruitment and funding.

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

药物 / 成分：Durvalumab、Tremelimumab

登记的停止原因（原文）：In compliance with current legislation applicable to Clinical Trials, following the instructions of the Spanish Agency for Medicines and Health Products.

Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation

药物 / 成分：Oxygen gas

登记的停止原因（原文）：Not possible to include patients at the required speed

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

药物 / 成分：Atezolizumab、Tiragolumab、Carboplatin、Cisplatin

登记的停止原因（原文）：Study was terminated as data became available from Phase 3 trials of perioperative regimens combining chemotherapy with immunotherapy showing improved efficacy outcomes versus chemotherapy alone.

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

药物 / 成分：CVL-871 1.0 mg、CVL-871 3.0 mg、Placebo

登记的停止原因（原文）：Sponsor Decision - Not Safety Related

Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease

药物 / 成分：RoadMAB precision dashboard、Infliximab precision dosing

登记的停止原因（原文）：This was the Pilot study. The larger, confirmatory study has started

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

药物 / 成分：ATA3219

登记的停止原因（原文）：Financial reasons

Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis

药物 / 成分：Deucravacitinib

登记的停止原因（原文）：Terminated early due to lack of expected efficacy. Three participants were enrolled but none completed the study.

Next Generation Personalized Neuroblastoma Therapy

药物 / 成分：Biopsy、Next Generation Sequencing、Tumor Scans、Bone marrow Tests

登记的停止原因（原文）：The goals of Part 1 (molecular screening) were met, but lack of therapies to match molecular aberrations made Part 2 (treatment) no longer feasible.

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

药物 / 成分：Decitabine、Laboratory Biomarker Analysis、Venetoclax

登记的停止原因（原文）：\<75% participation

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

药物 / 成分：Vascular Biogenics (VB)-111、Nivolumab

登记的停止原因（原文）：Interim analysis indicated limited efficacy

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

药物 / 成分：Tazemetostat、Abiraterone/prednisone、Enzalutamide

登记的停止原因（原文）：The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study. There were no safety concerns.

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

药物 / 成分：Voxelotor、Placebo

登记的停止原因（原文）：Emerging clinical data evaluated by Pfizer and shared with regulatory authorities indicates that the risk profile of voxelotor in people with SCD exceeds the benefits observed in previously generated global research and requires further assessment.

Crofelemer for Functional Diarrhea

药物 / 成分：Crofelemer、Placebo

登记的停止原因（原文）：low enrollment

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

药物 / 成分：Toripalimab + Chidamide

登记的停止原因（原文）：Five patients were enrolled in the study, but no treatment response was observed and all the patients had the best of response of prgressive disease. Given the lack of efficacy, the trial was terminated.

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

药物 / 成分：Brexucabtagene Autoleucel、Cyclophosphamide、Fludarabine

登记的停止原因（原文）：Sponsor decision to terminate study.